1 Min Read
April 17 (Reuters) - Basilea Pharmaceutica AG:
* LICENSES LATE-STAGE ONCOLOGY DRUG CANDIDATE DERAZANTINIB FROM ARQULE Source text for Eikon: Further company coverage: (Gdynia Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.